Acelyrin Misses Topline in Phase 2b/3 Study of Izokibep for Uveitis

 Phase 2b/3 trial of izokibep did not meet primary endpoint; secondary endpoints also did not achieve statistical significance

Company continues focus on development of subcutaneous lonigutamab in thyroid eye disease, with initiation of Phase 3 program on schedule for Q1 2025

$562.4 million in cash, cash equivalents, and short-term marketable securities on September 30, 2024 projected to provide runway to mid-2027, including completion of planned Phase 3 trials and BLA-enabling activities for lonigutamab as well as selective pipeline expansion

https://www.globenewswire.com/news-release/2024/12/10/2994971/0/en/ACELYRIN-INC-Announces-Topline-Results-From-Phase-2b-3-Study-of-Izokibep-for-the-Treatment-of-Uveitis.html